Microbiome-Based Bone Health Research

Pendulum Therapeutics Expands Collaboration with Mayo Clinic

Pendulum Therapeutics has expanded its clinical research collaboration with Mayo Clinic, one of the most respected medical institutions in the world, to investigate microbiome-based interventions for bone health in breast cancer patients, the gut-skin axis, and improving the menopause transition. This announcement builds on a relationship that began in 2013.

As part of the inquiry into bone health, gut-skin axis, and menopause transition, the research collaboration relies on Pendulum's portfolio of microbiome-targeted products along with its expertise in strain isolation, anaerobic manufacturing, DNA sequencing, and clinical validation. Mayo Clinic investigators will evaluate these new clinical studies.

Pendulum already has a track record of rigorous clinical research, having developed Glucose Control, the first probiotic clinically shown to reduce A1C in people with type 2 diabetes.

前往原文 ↗